Trials / Completed
CompletedNCT05468346
Study on the Body Mass Balance and Biotransformation of [14C]-HEC585
Clinical Trial of Absorption, Metabolism and Excretion of [14C]-HEC585 in Chinese Adult Male Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Sunshine Lake Pharma Co., Ltd. · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This is a single-centre, open-label, non-randomised, single-dose study in healthy male subjects designed to assess the mass balance and biotransformation of \[14C\]-HEC-585.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C]-HEC585 | Single Dose = Solution containing 200 mg/100 µCi \[14C\]-HEC585 |
Timeline
- Start date
- 2022-07-26
- Primary completion
- 2022-08-14
- Completion
- 2022-08-29
- First posted
- 2022-07-21
- Last updated
- 2023-04-13
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05468346. Inclusion in this directory is not an endorsement.